IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Core Insights - IceCure Medical Ltd. has promoted Shay Levav to Chief Operating Officer to enhance operational effectiveness and capitalize on the commercial momentum following FDA marketing clearance for ProSense® [1][2] - ProSense® is the first FDA-authorized device for local treatment of early-stage, low-risk breast cancer, specifically for women aged 70 and above [3][4] - The ProSense® system utilizes liquid nitrogen for cryoablation, offering a minimally invasive alternative to surgical tumor removal, with applications in various cancers [4][6] Company Developments - The appointment of Shay Levav is expected to strengthen IceCure's operational foundation as the company expands its presence in the U.S. market [2] - Levav has been instrumental in the clinical and regulatory processes for ProSense® and will continue to oversee Regulatory Affairs, Quality Assurance, and Clinical Affairs in his new role [1][2] Product Overview - ProSense® enhances patient care by accelerating recovery, reducing pain, and minimizing surgical risks, making it suitable for office-based procedures [5] - The system is designed for the treatment of benign and cancerous lesions in various organs, including the breast, kidney, lung, and liver [4][6]